Why can a patient have a stroke while on anticoagulant therapy (blood thinners)?

Why Strokes Occur Despite Anticoagulation

Strokes happen in anticoagulated patients primarily due to subtherapeutic anticoagulation (inadequate dosing or poor INR control), medication non-adherence, or competing non-cardioembolic stroke mechanisms unrelated to atrial fibrillation. 1

Primary Mechanisms

The 2024 ESC guidelines explicitly state that one-third of AF patients presenting with ischemic stroke are already on anticoagulation, with heterogeneous causes 1. The key mechanisms include:

1. Subtherapeutic Anticoagulation

• For warfarin patients: 91.7% of patients on vitamin K antagonists who had breakthrough strokes had admission INR <2.0 2
• For DOACs: 43% of patients were prescribed subtherapeutic doses 2
• Poor time in therapeutic range (TTR <70%) significantly increases stroke risk even on warfarin 1

2. Medication Non-Adherence

• Only 63.3% of anticoagulated stroke patients demonstrated good adherence 2
• Interestingly, adherence was significantly better with warfarin (83.3%) compared to DOACs (54.8%) 2
• Non-adherence is a modifiable risk factor that clinicians often overlook

3. Competing Stroke Mechanisms

• Large artery atherosclerosis (carotid stenosis, intracranial stenosis)
• Small vessel disease (lacunar strokes)
• These non-cardioembolic mechanisms occur independently of AF and are not prevented by anticoagulation 1

4. Residual Risk Despite Adequate Anticoagulation

• Even with optimal anticoagulation, there remains an irreducible residual stroke risk 1
• Anticoagulation significantly reduces but does not eliminate thromboembolic risk
• Patients with breakthrough strokes are more likely to have uncontrolled cardiovascular risk factors 1

Critical Clinical Actions

When evaluating a stroke on anticoagulation:

1. Immediately check anticoagulation levels:

   • INR for warfarin patients (target 2.0-3.0)
   • DOAC levels if available
   • This laboratory assessment may reveal an amenable cause 1

2. Verify medication adherence:

   • Direct questioning about missed doses
   • Pharmacy refill records
   • Use validated tools like the Brief Medication Questionnaire

3. Assess dosing appropriateness:

   • Review prescribed dose against patient's renal function, age, weight, and drug interactions
   • Nearly half of DOAC patients may be on inappropriate doses 2

4. Investigate alternative stroke mechanisms:

   • Carotid imaging for large artery disease
   • MRI patterns suggesting small vessel disease
   • These require different secondary prevention strategies

Common Pitfalls to Avoid

Do NOT routinely switch anticoagulants after breakthrough stroke. The 2024 ESC guidelines explicitly state that switching from one DOAC to another, or from a DOAC to warfarin, has no proven efficacy and is not recommended 1. The exception is switching from warfarin to a DOAC when TTR is inadequate (<70%) or there are concerns about intracranial bleeding risk.

Do NOT assume the anticoagulant "failed." In the majority of cases, stroke occurrence is explained by correctable factors (subtherapeutic dosing, poor adherence, or non-cardioembolic etiology), not anticoagulant inefficacy 2.

Management Algorithm

1. Obtain anticoagulation level (INR or DOAC level)
2. If subtherapeutic: Optimize dosing and address adherence barriers
3. If therapeutic: Complete stroke workup for alternative mechanisms (carotid ultrasound, MRI with vessel imaging)
4. Address cardiovascular risk factors: Hypertension, diabetes, hyperlipidemia control 1
5. Consider switching from warfarin to DOAC only if TTR <70% or recurrent issues with INR control 1
6. Do NOT switch between DOACs without clear rationale beyond "breakthrough stroke" 1

The evidence strongly indicates that most breakthrough strokes represent preventable failures in anticoagulation delivery rather than true treatment failures, making systematic evaluation of these correctable factors the priority over changing anticoagulant agents.